STAT Plus: What’s next for CAR-T and TCR? Five biotech execs on the lofty goals, the scientific challenges, and the looming price questions
ELAINE THOMPSON/AP
The narrow field of cell therapies could soon be used to treat far more common tumors, autoimmune diseases, or even viruses, biotech executives predicted.
.png)
No hay comentarios:
Publicar un comentario